Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-72551 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PXR Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 0.45 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress.
Sári Z, Mikó E, Kovács T, Jankó L, Csonka T, Lente G, Sebő É, Tóth J, Tóth D, Árkosy P, Boratkó A, Ujlaki G, Török M, Kovács I, Szabó J, Kiss B, Méhes G, Goedert JJ, Bai P
Cancers 2020 Aug 25;12(9)
Cancers 2020 Aug 25;12(9)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of NR1I2 in HL-60 cell lysate using 35 µg of protein per lane. Samples were incubated with NR1I2 polyclonal antibody (Product # PA5-72551).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of NR1I2 in HL-60 cell lysate using 35 µg of protein per lane. Samples were incubated with NR1I2 polyclonal antibody (Product # PA5-72551).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of NR1I2 in HepG2 cells using confocal microscopy. Sample was incubated with NR1I2 polyclonal antibody (Product # PA5-72551) followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green) secondary antibody. Actin filaments were labeled with Alexa Fluor 555 Phalloidin (red) and DAPI was used to stain the cell nuclei (blue).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of NR1I2 in paraffin-embedded human hepatocarcinoma tissue. Samples were incubated with NR1I2 polyclonal antibody (Product # PA5-72551) followed by a peroxidase-conjugate secondary antibody and DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of NR1I2 in HL-60 cells (bottom histogram) compared to a negative control cell (top histogram). Samples were incubated with NR1I2 polyclonal antibody (Product # PA5-72551) followed by a FITC conjugated goat anti-rabbit secondary antibody.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 8 Higher intratumoral expression of pregnane X receptor (PXR) and nuclear aryl hydrocarbon receptor (AHR) shows correlation with low-grade and lower-mitosis breast cancers. ( A ) TMA was stained with the indicated antibodies. A typical staining pattern is shown. The bar is equivalent of 50 um. Cases in TMA were scored for receptor expression using the H-score system. ( B - E ) H-score of the nuclear expression of the AHR receptor were related to ( B ) stage of the disease, ( C ) mitosis score, ( D ) tubule formation, and ( E ) histological subtype. ( F - H ) H-score of the expression of PXR receptor were related to ( F ) grade of the disease, ( G ) mitosis score, and ( H ) mitotic index. Statistical significance on panels B and F was determined using an ANOVA test followed by Dunnett's post-hoc test, while on panels C, D, E, G, and H, Student's t -test was used. Stage 0 (in situ carcinoma) and stage 1 patients, Mitosis score 2 and 3 patients, and tubule formation score 1 and 2 patients were handled together due to the low number of cases. Abbreviations: Aryl hydrocarbon receptor (AHR), Pregnane X receptor (PXR), no special type (NOS). *, ** and *** indicate statistically significant difference between control and treated samples at p < 0.05, p < 0.01 or p < 0.001, respectively.
